B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
AYTU
Aytu BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
EXXUA showed early commercial traction, including $2.4 million of Q3 revenue, more than 1,300 prescriptions, over 450 prescribers, and early refill activity. Continued adoption and access conversion could make EXXUA the primary growth driver.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
ADHD and pediatric revenue are declining amid strategic reprioritization and generic competition.
Momentum
100
Value
53
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.45 · Bull $3.40 · Bear $1.45Analysis 2026-08-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.50
Why
Momentum100 · Δ7d -
Value53 · Δ7d -0.0
Sentiment79 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • ADHD and pediatric revenue are declining amid strategic reprioritization and generic competition.
- • Analyst revisions, consensus estimates, options data, short interest, social coverage, and post-earnings price-reaction analysis are unavailable.
- • The earnings update showed substantial legacy-portfolio contraction, negative adjusted EBITDA, and a net loss.
Catalyst clock
2026-11-22
EXXUA access and commercial expansion
Lead driver: Sentiment · See AI snapshot
Momentum
100
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
53
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-15.5
Sentiment
79
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.5 / Value 53.4 / Sentiment 79.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.45
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$25.33M
Beta
0.37
Shares Out
10.73M
P/E (TTM)
15.7
P/S (TTM)
0.46
P/FCF (TTM) · Derived
6.84
Rev YoY
-32.7%
EPS YoY
-353.1%
Gross Margin
+60.1%
Op Margin
-12.2%
Net Debt
-$8.02M
Current Ratio
1.12
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data